Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
18 avr. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
14 avr. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
24 mars 2022 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA nephropathy, and islet cell transplantation...
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
17 mars 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook
14 févr. 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart (AT-1501) in Amyotrophic Lateral Sclerosis (ALS) Announces USAN Approval of Generic Name “tegoprubart” for lead...
Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference
08 févr. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Orgenesis to Present at the 2017 Marcum MicroCap Conference
12 juin 2017 08h00 HE
|
Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Jun 12, 2017) - Orgenesis Inc. (OTCQB: ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and...
Orgenesis Provides Update Regarding AIP Cell-Based Therapy for Type 1 Diabetes, MaSTherCell Cell Manufacturing Subsidiary and Overall Financial Condition
08 mars 2017 09h00 HE
|
Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Mar 8, 2017) - Orgenesis Inc. (OTCQB: ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and...
Orgenesis Approved for Euro 12.3 Million European Grant for Further Development of Its Type 1 Diabetes Program
13 févr. 2017 08h30 HE
|
Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Feb 13, 2017) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its Belgian...
Servier Appoints MaSTherCell for the Development of its CAR-T Cell Therapy Manufacturing Platform
20 janv. 2017 09h00 HE
|
Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Jan 20, 2017) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its...